BACKGROUND: Findings on the impact of cannabis use on the course of schizophrenia are inconsistent and not conclusive. AIMS: To study the effect of cannabis use on the course of schizophrenia taking into account the effects of the quantity of cannabis use and important confounders. METHODS: Prospective cohort study with assessments of symptoms, confounders and hospitalizations at baseline, 6 month and 12 month follow up. RESULTS: In a representative cohort of 145 male patients with schizophrenia, 68 (46.9%) used cannabis. Mean age at onset of schizophrenia in cannabis using patients was significantly lower than in non-cannabis using patients. No other cross-sectional demographic or clinical differences were observed between users and non-users. In a series of longitudinal analyses, cannabis use was not associated with differences in psychopathology, but relapse in terms of the number of hospitalizations was significantly higher in cannabis using patients compared to non-cannabis using patients. CONCLUSIONS: Patients with schizophrenia using cannabis are more frequently hospitalized than non-cannabis using patients but do not differ with respect to psychopathology. Possible explanations for these findings are discussed.
BACKGROUND: Findings on the impact of cannabis use on the course of schizophrenia are inconsistent and not conclusive. AIMS: To study the effect of cannabis use on the course of schizophrenia taking into account the effects of the quantity of cannabis use and important confounders. METHODS: Prospective cohort study with assessments of symptoms, confounders and hospitalizations at baseline, 6 month and 12 month follow up. RESULTS: In a representative cohort of 145 male patients with schizophrenia, 68 (46.9%) used cannabis. Mean age at onset of schizophrenia in cannabis using patients was significantly lower than in non-cannabis using patients. No other cross-sectional demographic or clinical differences were observed between users and non-users. In a series of longitudinal analyses, cannabis use was not associated with differences in psychopathology, but relapse in terms of the number of hospitalizations was significantly higher in cannabis using patients compared to non-cannabis using patients. CONCLUSIONS:Patients with schizophrenia using cannabis are more frequently hospitalized than non-cannabis using patients but do not differ with respect to psychopathology. Possible explanations for these findings are discussed.
Authors: Jibran Y Khokhar; Lucas L Dwiel; Angela M Henricks; Wilder T Doucette; Alan I Green Journal: Schizophr Res Date: 2017-04-14 Impact factor: 4.939
Authors: Justin Davis; Harris Eyre; Felice N Jacka; Seetal Dodd; Olivia Dean; Sarah McEwen; Monojit Debnath; John McGrath; Michael Maes; Paul Amminger; Patrick D McGorry; Christos Pantelis; Michael Berk Journal: Neurosci Biobehav Rev Date: 2016-04-09 Impact factor: 8.989
Authors: Diego Quattrone; Laura Ferraro; Giada Tripoli; Caterina La Cascia; Harriet Quigley; Andrea Quattrone; Hannah E Jongsma; Simona Del Peschio; Giusy Gatto; Charlotte Gayer-Anderson; Peter B Jones; James B Kirkbride; Daniele La Barbera; Ilaria Tarricone; Domenico Berardi; Sarah Tosato; Antonio Lasalvia; Andrei Szöke; Celso Arango; Miquel Bernardo; Julio Bobes; Cristina Marta Del Ben; Paulo Rossi Menezes; Pierre-Michel Llorca; Jose Luis Santos; Julio Sanjuán; Andrea Tortelli; Eva Velthorst; Lieuwe de Haan; Bart P F Rutten; Michael T Lynskey; Tom P Freeman; Pak C Sham; Alastair G Cardno; Evangelos Vassos; Jim van Os; Craig Morgan; Ulrich Reininghaus; Cathryn M Lewis; Robin M Murray; Marta Di Forti Journal: Psychol Med Date: 2020-03-18 Impact factor: 7.723
Authors: Arnold P M van der Lee; Adriaan Hoogendoorn; Lieuwe de Haan; Aartjan T F Beekman Journal: BMC Psychiatry Date: 2021-06-29 Impact factor: 3.630